MCID: MCR004
MIFTS: 50

Macroglobulinemia malady

Categories: Metabolic diseases

Aliases & Classifications for Macroglobulinemia

Aliases & Descriptions for Macroglobulinemia:

Name: Macroglobulinemia 12 14
Waldenstrom Macroglobulinemia 69
Primary Macroglobulinemia 12

Classifications:



Summaries for Macroglobulinemia

MalaCards based summary : Macroglobulinemia, also known as waldenstrom macroglobulinemia, is related to mu chain disease and angiosarcoma. An important gene associated with Macroglobulinemia is CD40LG (CD40 Ligand), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Dexamethasone and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and b cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Wikipedia : 71 Macroglobulinemia is the presence of increased levels of macroglobulins in the circulating blood. It is... more...

Related Diseases for Macroglobulinemia

Diseases related to Macroglobulinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 165)
id Related Disease Score Top Affiliating Genes
1 mu chain disease 29.5 CD40LG MYD88
2 angiosarcoma 28.9 CD40LG CXCR4 HAS1 ITGAE MYD88 PAX5
3 waldenstrom macroglobulinemia 12.3
4 macroglobulinemia, waldenstrom 1 12.2
5 macroglobulinemia, waldenstrom 2 11.8
6 waldenstroem's macroglobulinemia 11.7
7 lymphoplasmacytic lymphoma 11.7
8 schnitzler syndrome 11.2
9 monoclonal gammopathy of uncertain significance 11.1
10 lymphoma 10.4
11 hyperparathyroidism, primary, caused by water clear cell hyperplasia 10.2 CD40LG TNFSF13B
12 colonic benign neoplasm 10.2 CD27 CD40LG MYD88
13 generalized atherosclerosis 10.2 CD40LG IL6
14 hallucinogen dependence 10.1 CD40LG IL6 MYD88
15 lacrimal gland carcinoma 10.1 CD27 CD40LG TNFSF13B
16 multiple myeloma 10.1
17 inner ear disease 10.1 CD40LG IL6
18 diabetic angiopathy 10.1 BTK CD40LG
19 carotenemia 10.1 CD40LG IL6 ITGAE
20 paramyloidosis 10.1 CD40LG CXCR4 MYD88 PAX5
21 ciliary body spindle cell melanoma 10.1 BTK CD40LG
22 leukemia 10.1
23 primary tubular proximal acidosis 10.1 CXCL12 MYD88 PAX5
24 islet cell tumor 10.1 CXCL12 CXCR4 PAX5
25 al gazali sabrinathan nair syndrome 10.0 CXCL12 CXCR4
26 exophthalmos 10.0 CD40LG CXCR4 IL6
27 articulation disorder 10.0 CD40LG IL6 TNFSF13B
28 b-cell lymphomas 10.0
29 rhabdomyosarcoma 10.0 CXCL12 CXCR4 MYD88 PAX5
30 amyloidosis 10.0
31 arteriosclerosis 10.0 BTK CD40LG CXCR4 MYD88
32 anus leiomyosarcoma 9.9 CD40LG CXCL12 CXCR4 IL6
33 neuropathy 9.9
34 pancreas disease 9.9 BTK CD40LG CXCL12
35 melanoma metastasis 9.9 AKT1 BTK CD40LG
36 diffuse large b-cell lymphoma 9.9
37 hepatitis 9.9
38 cryoglobulinemia 9.9
39 chronic lymphocytic leukemia 9.8
40 childhood choriocarcinoma of the testis 9.8 BTK CD40LG TNFRSF13B
41 glomerulonephritis 9.8
42 splenic marginal zone lymphoma 9.8
43 nephrotic syndrome 9.8
44 hepatitis c 9.8
45 retinitis 9.8
46 hodgkin lymphoma 9.7
47 hemolytic anemia 9.7
48 marginal zone b-cell lymphoma 9.7
49 thrombocytopenia 9.7
50 polyneuropathy 9.7

Graphical network of the top 20 diseases related to Macroglobulinemia:



Diseases related to Macroglobulinemia

Symptoms & Phenotypes for Macroglobulinemia

GenomeRNAi Phenotypes related to Macroglobulinemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.32 AKT1 CD40LG CXCR4 MYD88
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.32 AKT1 BTK CD27 CD40LG CXCR4 MYD88

MGI Mouse Phenotypes related to Macroglobulinemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.93 AKT1 BTK CD27 CD40LG CXCL12 CXCR4
2 cellular MP:0005384 9.91 AKT1 BTK CD27 CD40LG CXCL12 CXCR4
3 immune system MP:0005387 9.73 AKT1 BTK CD27 CD40LG CXCL12 CXCR4
4 neoplasm MP:0002006 9.17 AKT1 BTK CXCR4 IL6 MYD88 PAX5

Drugs & Therapeutics for Macroglobulinemia

Drugs for Macroglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 369)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
2
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 33419-42-0 36462
3
Cytarabine Approved, Investigational Phase 4,Phase 1,Phase 2 147-94-4 6253
4
Methotrexate Approved Phase 4,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
6
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
7
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 179324-69-7 387447 93860
8
Thiotepa Approved Phase 4,Phase 2,Phase 3 52-24-4 5453
9
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
10
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-24-8 5755
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 1 83-43-2 6741
12
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
13
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
15 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
16 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
19 Folic Acid Antagonists Phase 4,Phase 2,Phase 1,Early Phase 1
20 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
21 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
22 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 1,Early Phase 1
23 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Dexamethasone 21-phosphate Phase 4,Phase 3,Phase 2,Phase 1
26 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Angiogenesis Inhibitors Phase 4,Phase 1,Phase 2
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Angiogenesis Modulating Agents Phase 4,Phase 1,Phase 2
31 Vitamin B Complex Phase 4,Phase 2,Phase 1,Early Phase 1
32 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Immunoglobulins Phase 4,Phase 2,Phase 1,Early Phase 1
35 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
36 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Protective Agents Phase 4,Phase 2,Phase 1
38 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
39 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
41 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
42 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
43 Antibodies Phase 4,Phase 2,Phase 1,Early Phase 1
44 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1
47 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Prednisolone acetate Phase 4,Phase 2,Phase 1
50 Neuroprotective Agents Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 443)
id Name Status NCT ID Phase
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
2 The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia Recruiting NCT02844322 Phase 4
3 Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia Recruiting NCT02844361 Phase 4
4 The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM Recruiting NCT02844309 Phase 4
5 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4
6 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
7 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
8 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
9 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3
10 Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma Completed NCT00608374 Phase 3
11 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3
12 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
13 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3
14 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
15 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
16 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
17 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
18 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
19 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
20 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3
21 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
22 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
23 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
24 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
25 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
26 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
27 A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Recruiting NCT03053440 Phase 3
28 Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia Recruiting NCT01788020 Phase 3
29 Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3
30 Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Active, not recruiting NCT02165397 Phase 3
31 A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneo Active, not recruiting NCT01461928 Phase 3
32 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Active, not recruiting NCT01231412 Phase 3
33 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3
34 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Active, not recruiting NCT00801281 Phase 3
35 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732926 Phase 3
36 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732913 Phase 3
37 A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia Unknown status NCT01142011 Phase 2
38 Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia Unknown status NCT00041379 Phase 1, Phase 2
39 Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia Unknown status NCT01046006 Phase 2
40 Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia Unknown status NCT00003512 Phase 2
41 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2
42 Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Unknown status NCT01044745 Phase 2
43 Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy Unknown status NCT01035463 Phase 1, Phase 2
44 Comparison of Fludarabine Plus Total-Body Irradiation With Combination Chemotherapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Unknown status NCT00041288 Phase 2
45 Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma Unknown status NCT00937183 Phase 1, Phase 2
46 Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers Unknown status NCT00003163 Phase 2
47 Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma Unknown status NCT00397800 Phase 1, Phase 2
48 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2
49 Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia Unknown status NCT01016990 Phase 2
50 Sildenafil Citrate in Waldenstrom's Macroglobulinemia Completed NCT00165295 Phase 2

Search NIH Clinical Center for Macroglobulinemia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Macroglobulinemia

Anatomical Context for Macroglobulinemia

MalaCards organs/tissues related to Macroglobulinemia:

39
Bone, Bone Marrow, B Cells, Liver, Spleen, Lymph Node, T Cells

Publications for Macroglobulinemia

Articles related to Macroglobulinemia:

(show top 50) (show all 775)
id Title Authors Year
1
WaldenstrAPm macroglobulinemia: 2017 update on diagnosis, risk stratification, and management. ( 28094456 )
2017
2
Diagnosis and Management of WaldenstrAPm Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. ( 28056114 )
2017
3
Allogeneic Transplantation for Relapsed WaldenstrAPm Macroglobulinemia and Lymphoplasmacytic Lymphoma. ( 27789362 )
2017
4
MYD88 L265P mutation in cutaneous involvement by WaldenstrAPm macroglobulinemia. ( 28370087 )
2017
5
UNUSUAL SEROUS RETINAL DETACHMENT IN A PATIENT WITH WALDENSTROM MACROGLOBULINEMIA: A CASE REPORT. ( 28106626 )
2017
6
Genomics, Signaling, and Treatment of WaldenstrAPm Macroglobulinemia. ( 28294689 )
2017
7
Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia. ( 28043164 )
2017
8
Waldenstrom macroglobulinemia presenting as a bilateral subdural chronic hematoma. ( 28262409 )
2017
9
WaldenstrAPm Macroglobulinemia: Review of Pathogenesis and Management. ( 28366781 )
2017
10
A phase II Bayesian sequential clinical trial in advanced WaldenstrAPm macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone. ( 28395585 )
2017
11
New developments in the management of WaldenstrAPm macroglobulinemia. ( 28331368 )
2017
12
Acquired mutations associated with ibrutinib resistance in WaldenstrAPm macroglobulinemia. ( 28235842 )
2017
13
Prospective, multicenter clinical trial of everolimus as primary therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). ( 27836860 )
2016
14
Learning from Waldenstrom Macroglobulinemia. ( 27825458 )
2016
15
WaldenstrAPm's macroglobulinemia: a clinical perspective in the era of novel therapeutics. ( 26598544 )
2016
16
"All the soarings of my mind begin in my blood:" central nervous system complication of WaldenstrAPm macroglobulinemia. ( 27414991 )
2016
17
Resolution of WaldenstrAPm Macroglobulinemia-Associated Autoimmune Hemolysis With Ibrutinib. ( 27170696 )
2016
18
Prognostic factors and indications for treatment of WaldenstrAPm's Macroglobulinemia. ( 27825464 )
2016
19
Monoclonal gammopathy of undetermined significance and WaldenstrAPm's macroglobulinemia. ( 27825465 )
2016
20
Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection. ( 26942591 )
2016
21
Immunoglobulin M 'Flare' Seen in a Case of Waldenstrom's Macroglobulinemia: Successfully Managed by Therapeutic Plasma Exchange. ( 27408378 )
2016
22
Poor Correlation between Pneumococcal IgG and IgM Titers and Opsonophagocytic Activity in Vaccinated Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia. ( 26912783 )
2016
23
A 44-Year-Old Man with Waldenstrom Macroglobulinemia and Bilateral Maxillary Sinusitis. ( 27840358 )
2016
24
Novel therapeutic targets in Waldenstrom macroglobulinemia. ( 27825468 )
2016
25
Exome sequencing reveals recurrent germline variants in patients with familial Waldenstrom's macroglobulinemia. ( 26903547 )
2016
26
Systemic AL amyloidosis associated with WaldenstrAPm macroglobulinemia: an unusual presenting complication. ( 27127826 )
2016
27
Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in WaldenstrAPm macroglobulinemia. ( 26635033 )
2016
28
The role of stem cell transplantation in Waldenstrom's macroglobulinemia. ( 27825469 )
2016
29
Preclinical models of WaldenstrAPm's macroglobulinemia and drug resistance. ( 27825463 )
2016
30
Transcriptome sequencing reveals a profile that corresponds to genomic variants in WaldenstrAPm macroglobulinemia. ( 27301862 )
2016
31
Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected WaldenstrAPm macroglobulinemia/lymphoplasmacytic lymphoma. ( 27890075 )
2016
32
Idelalisib in WaldenstrAPm macroglobulinemia: high incidence of hepatotoxicity. ( 27562445 )
2016
33
Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment. ( 27696269 )
2016
34
Ibrutinib in WaldenstrAPm macroglobulinemia: latest evidence and clinical experience. ( 27493708 )
2016
35
Atrial fibrillation associated with ibrutinib in WaldenstrAPm macroglobulinemia. ( 26994323 )
2016
36
Evolution of Management and Outcomes in WaldenstrAPm Macroglobulinemia: A Population-Based Analysis. ( 27473042 )
2016
37
Histological transformation to diffuse large B-cell lymphoma in patients with WaldenstrAPm macroglobulinemia. ( 27415417 )
2016
38
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or WaldenstrAPm's macroglobulinemia. ( 26800393 )
2016
39
Targeting cell adhesion and homing as strategy to cure WaldenstrAPm's macroglobulinemia. ( 27825462 )
2016
40
Massive petechiae as an initial symptom of WaldenstrAPm's macroglobulinemia. ( 26748624 )
2016
41
Future therapeutic options for patients with WaldenstrAPm macroglobulinemia. ( 27825467 )
2016
42
Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells. ( 27813535 )
2016
43
IMAGES IN CLINICAL MEDICINE. Hyperviscosity-Related Retinopathy in WaldenstrAPm's Macroglobulinemia. ( 26735995 )
2016
44
Clonal B cells in WaldenstrAPm's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling. ( 26867669 )
2016
45
Response rate to the treatment of WaldenstrAPm macroglobulinemia: A meta-analysis of the results of clinical trials. ( 27423974 )
2016
46
WALDENSTRA9M'S MACROGLOBULINEMIA MASQUERADING AS BIRDSHOT CHORIORETINOPATHY. ( 27124793 )
2016
47
Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia. ( 27135784 )
2016
48
DUAL NAMPT AND BTK TARGETING LEADS TO SYNERGISTIC KILLING OF WALDENSTROM`S MACROGLOBULINEMIA CELLS REGARDLESS OF MYD88 AND CXCR4 SOMATIC MUTATIONS STATUS. ( 27287071 )
2016
49
BACH2 promotes indolent clinical presentation in WaldenstrAPm macroglobulinemia. ( 27285766 )
2016
50
Waldenstrom macroglobulinemia: prognosis and management. ( 26849012 )
2016

Variations for Macroglobulinemia

Expression for Macroglobulinemia

Search GEO for disease gene expression data for Macroglobulinemia.

Pathways for Macroglobulinemia

Pathways related to Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 27)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.69 AKT1 BTK CD27 CD40LG CXCL12 CXCR4
2
Show member pathways
13.5 AKT1 BTK CD27 CD40LG CXCL12 CXCR4
3
Show member pathways
13.39 AKT1 BTK CXCL12 CXCR4 IL6 ITGAE
4
Show member pathways
13.22 AKT1 CD27 CD40LG IL6 MYD88 TNFRSF13B
5
Show member pathways
13.12 AKT1 BTK CD27 CD40LG CXCL12 CXCR4
6
Show member pathways
12.91 AKT1 BTK CXCL12 IL6 ITGAE
7
Show member pathways
12.84 AKT1 BTK CD27 CD40LG CXCL12 CXCR4
8
Show member pathways
12.71 CD40LG CXCL12 CXCR4 IL6 TNFRSF13B TNFSF13B
9
Show member pathways
12.55 AKT1 CD40LG CXCL12 IL6 MYD88 TNFSF13B
10 12.53 AKT1 CXCL12 CXCR4 IL6
11
Show member pathways
12.52 AKT1 CD27 CD40LG CXCR4
12
Show member pathways
12.44 AKT1 BTK CD27 CD40LG MYD88 TNFRSF13B
13 12.3 BTK CD40LG CXCL12 CXCR4 MYD88 PAX5
14 11.96 AKT1 CXCR4 ITGAE
15 11.74 CXCL12 IL6 TNFSF13B
16
Show member pathways
11.71 CD27 CD40LG TNFRSF13B TNFSF13B
17 11.7 BTK CD40LG CXCL12 MYD88 TNFSF13B
18 11.66 AKT1 CXCL12 CXCR4
19
Show member pathways
11.63 CD40LG TNFRSF13B TNFSF13B
20 11.59 CXCL12 CXCR4 IL6
21 11.56 AKT1 CXCL12 CXCR4
22 11.42 CD40LG IL6 MYD88
23 11.29 BTK CD40LG TNFRSF13B
24 11.28 CD27 CD40LG CXCR4 PAX5 TNFRSF13B
25 11.2 CXCL12 CXCR4 TNFRSF13B
26 11.06 BTK CD40LG CXCL12 IL6 TNFSF13B
27 10.95 CD40LG IL6 ITGAE PAX5 TNFRSF13B TNFSF13B

GO Terms for Macroglobulinemia

Cellular components related to Macroglobulinemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.73 AKT1 BTK CD27 CD40LG CXCL12 CXCR4
2 external side of plasma membrane GO:0009897 9.1 CD27 CD40LG CXCL12 IL6 ITGAE TNFRSF13B

Biological processes related to Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 21)
id Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.96 AKT1 BTK CD27 CXCR4 MYD88
2 negative regulation of apoptotic process GO:0043066 9.88 AKT1 CD27 CD40LG IL6 MYD88
3 immune response GO:0006955 9.85 CD27 CD40LG CXCL12 IL6 TNFSF13B
4 regulation of cell proliferation GO:0042127 9.8 BTK CD27 IL6 MYD88
5 platelet activation GO:0030168 9.76 AKT1 CD40LG IL6
6 response to virus GO:0009615 9.74 CXCL12 CXCR4 MYD88
7 T cell costimulation GO:0031295 9.7 AKT1 CD40LG TNFSF13B
8 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.69 AKT1 CD27 IL6
9 positive regulation of T cell proliferation GO:0042102 9.61 CD40LG IL6 TNFSF13B
10 endocrine pancreas development GO:0031018 9.6 AKT1 IL6
11 B cell homeostasis GO:0001782 9.59 TNFRSF13B TNFSF13B
12 negative regulation of B cell proliferation GO:0030889 9.58 BTK TNFRSF13B
13 positive regulation of smooth muscle cell proliferation GO:0048661 9.58 AKT1 IL6 MYD88
14 positive regulation of B cell differentiation GO:0045579 9.55 BTK CD27
15 immunoglobulin mediated immune response GO:0016064 9.54 CD27 MYD88
16 response to heat GO:0009408 9.5 AKT1 CXCL12 IL6
17 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.46 BTK CD40LG IL6 MYD88
18 response to peptidoglycan GO:0032494 9.37 IL6 MYD88
19 immunoglobulin secretion GO:0048305 9.26 CD40LG TNFSF13B
20 tumor necrosis factor-mediated signaling pathway GO:0033209 9.26 CD27 CD40LG TNFRSF13B TNFSF13B
21 inflammatory response GO:0006954 9.1 AKT1 CD27 CD40LG CXCR4 IL6 MYD88

Molecular functions related to Macroglobulinemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 CD40LG CXCL12 IL6 TNFSF13B
2 receptor binding GO:0005102 9.02 BTK CXCL12 IL6 MYD88 TNFSF13B

Sources for Macroglobulinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....